Angion Biomedica Corp expected to post a loss of 43  cents a share - Earnings Preview

Elicio Therapeutics

13/05/2022 15:17

* Angion Biomedica Corp  ANGN.OQ   ANGN.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 16
(estimated). 
    * The Uniondale New York-based  company is expected to
report  a
147.6% increase in revenue to $918.75 thousand from $371
thousand a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Angion Biomedica
Corp is
for a loss of 43 cents per share. For the same quarter last
year, the company reported a loss of $1.56 per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Angion
Biomedica
Corp is $8​, above​ its last closing price of $1.35. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.66       -0.62      0.58      Beat    193.9
 Sep. 30 2021  -0.72       -0.72      -0.53     Beat    26.9
 Jun. 30 2021  -0.69       -0.69      -0.58     Beat    15.6​
 Mar. 31 2021  -0.62       -0.62      -1.56     Missed  -150.6
 ​​Dec.        -1.30       -1.30      -1.90     Missed  -46.2
 31 2020                                                
                                                        ​
 This summary was machine generated May 13 at 14:16 GMT.  All
figures in US dollars  unless otherwise stated